{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:17:33Z","timestamp":1793175453318,"version":"4.5.0"},"reference-count":25,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Pancreatic adenocarcinoma is an aggressive gastrointestinal malignancy with only a few long-term survivors even after radical surgery. Patients with ampullary cancer have a better prognosis but adjuvant therapy needs further improvement. Epithelial cell adhesion molecule (Ep-CAM) is strongly expressed in a variety of epithelial cancers and represents a promising target for immunological tumour therapy. Thus, the aim of this study was to investigate Ep-CAM expression and its potential prognostic impact in pancreatic and ampullary carcinomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Ep-CAM expression was investigated retrospectively by immunohistochemistry in paraffin-embedded primary tumour tissue samples from a series of consecutive patients with pancreatic (n\u200a=\u200a153) and ampullary cancer (n\u200a=\u200a34).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ep-CAM overexpression was observed in 85 of 153 pancreatic cancer specimens (56%) and in 29 of 34 ampullary cancer samples (85%). Overall, Ep-CAM failed to be an independent prognostic marker. However, subgroup analyses showed that Ep-CAM overexpression correlated with shorter overall survival among patients with ampullary cancer and advanced stage pancreatic cancer. In the latter subgroup, survival gradually worsened with increasing Ep-CAM scores. Furthermore, in ampullary cancer, Ep-CAM overexpression was found to correlate with tumour stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ep-CAM overexpression was detectable in the majority of cases with pancreatic and ampullary cancer. Therefore, Ep-CAM represents an attractive target for immune-based therapeutic interventions in these tumour entities. However, the prognostic value of Ep-CAM overexpression remains undetermined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp.2006.037333","type":"journal-article","created":{"date-parts":[[2006,6,14]],"date-time":"2006-06-14T21:00:52Z","timestamp":1150318852000},"page":"31-35","source":"Crossref","is-referenced-by-count":90,"title":["Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance"],"prefix":"10.1136","volume":"61","author":[{"given":"D","family":"Fong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Obrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Margreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Amberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Laimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tzankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Spizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2006,6,14]]},"reference":[{"key":"2025121322351558000_61.1.31.1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJM199202133260706","article-title":"Pancreatic carcinoma.","volume":"326","author":"Warshaw","year":"1992","journal-title":"N Engl J Med"},{"key":"2025121322351558000_61.1.31.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-255X(00)80105-5"},{"key":"2025121322351558000_61.1.31.3","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.139.5.1337"},{"key":"2025121322351558000_61.1.31.4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600143"},{"key":"2025121322351558000_61.1.31.5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/jcp.52.9.701","article-title":"Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target?","volume":"52","author":"Martin","year":"1999","journal-title":"J Clin Pathol"},{"key":"2025121322351558000_61.1.31.6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6602310","article-title":"Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.","volume":"92","author":"Prang","year":"2005","journal-title":"Br J Cancer"},{"key":"2025121322351558000_61.1.31.7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10443"},{"key":"2025121322351558000_61.1.31.8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21165"},{"key":"2025121322351558000_61.1.31.9","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.1998.16.5.1788","article-title":"Monoclonal antibody therapy for resected Dukes\u00e2\u0080\u0099C colorectal cancer: Seven-year outcome of a multicenter randomized trial.","volume":"16","author":"Riethmuller","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025121322351558000_61.1.31.10","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9"},{"key":"2025121322351558000_61.1.31.11","unstructured":"International Union Against Cancer (UICC). TNM Atlas: Illustrated Guide to the TNM\/pTNM-Classification of Malignant Tumors 4th edn. Berlin, Springer-Verlag, 1997."},{"key":"2025121322351558000_61.1.31.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03312-2"},{"key":"2025121322351558000_61.1.31.13","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.140.6.1519"},{"key":"2025121322351558000_61.1.31.14","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.013292"},{"key":"2025121322351558000_61.1.31.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0729"},{"key":"2025121322351558000_61.1.31.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0425"},{"key":"2025121322351558000_61.1.31.17","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1200\/jco.2005.23.16_suppl.2555","article-title":"A randomized placebo-controlled phase II study with the cancer vaccine candidate IGN101 in patients with epithelial cancers [abstract].","volume":"23","author":"Himmler","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025121322351558000_61.1.31.18","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/jco.2005.23.16_suppl.2557","article-title":"A multicenter phase II, open-label trial of multiple doses of cancer vaccine candidate IGN101 to evaluate efficacy against disseminated tumor cells in blood [abstract].","volume":"23","author":"Samonigg","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025121322351558000_61.1.31.19","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6711"},{"key":"2025121322351558000_61.1.31.20","first-page":"865","article-title":"Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation.","volume":"148","author":"Litvinov","year":"1996","journal-title":"Am J Pathol"},{"key":"2025121322351558000_61.1.31.21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207610"},{"key":"2025121322351558000_61.1.31.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0754"},{"key":"2025121322351558000_61.1.31.23","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000036787.59816.01"},{"key":"2025121322351558000_61.1.31.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0528"},{"key":"2025121322351558000_61.1.31.25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1242\/dev.121.6.1569","article-title":"Developmental biology of the pancreas.","volume":"121","author":"Slack","year":"1995","journal-title":"Development"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.2006.037333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T06:35:23Z","timestamp":1765694123000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.2006.037333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,14]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,12,21]]},"published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1136\/jcp.2006.037333"],"URL":"https:\/\/doi.org\/10.1136\/jcp.2006.037333","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,14]]}}}